Jens Bitsch-Norhave
Fortune : 713 $ au 31/08/2026
Fortune : 713 $ au 31/08/2026
Jens Bitsch-Norhave is currently Director at Evaxion AS since 2026.
Dr. Bitsch-Norhave also holds the position of Vice President & Early Innovation Partnering at Johnson & Johnson Innovation - JJDC, Inc. Dr. Bitsch-Norhave completed an MBA at Copenhagen Business School.
Dr. Bitsch-Norhave also earned graduate and doctorate degrees from the University of Copenhagen.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EVAXION A/S 0 % | 16/04/2026 | 2 376 ( 0 % ) | 713 $ | 31/08/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| EVAXION A/S | Directeur/Membre du Conseil | 16/04/2026 |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC invests in private and public companies located across the globe. The firm focuses on innovative medicine, health equity and medtech sectors. It provides financing for seed, early, and later stage capital requirements. | Private Equity Investor | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC invests in private and public companies located across the globe. The firm focuses on innovative medicine, health equity and medtech sectors. It provides financing for seed, early, and later stage capital requirements. | Finance |
Copenhagen Business School
Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Evaxion Biotech A/S
Evaxion Biotech A/S BiotechnologyHealth Technology Develops novel vaccines | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national